http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2609437-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_840e3673e962dde3e5975e5c8d3483a3 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
filingDate | 2011-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_785b1af8eb506594cac30185363dd44d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cb5dda68dd28f2b3928fab6e558a445 |
publicationDate | 2017-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2609437-T3 |
titleOfInvention | Method to evaluate the efficacy of a therapy with T1 cells in a subject |
abstract | A method for evaluating whether a human patient undergoing antigen-specific Tr1 cell therapy has a greater than 50% probability of responding to the treatment, said method comprising: - determining in vitro the antigen-specific proliferation of T cells contained in a sample of cells obtained from said patient between day 8 and day 30 after the last administration of antigen-specific Tr1 cell therapy, wherein said antigen-specific proliferation is specific for the antigen for which the Tr1 cells are directed, - comparing said antigen-specific proliferation of T cells to a standard reference wherein the standard reference is the antigen-specific proliferation of T cells contained in a sample obtained from said patient prior to antigen-specific Tr1 cell therapy, wherein said proliferation Antigen-specific is measured in vitro and is specific for the antigen for which it is tested. targeting Tr1 cells, thereby determining whether the patient has greater than a 50% chance of responding to said antigen-specific Tr1 cell therapy. |
priorityDate | 2010-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1225.